Diabetes market in flux as FDA mandates new warnings

The Los Angeles Times notes that the FDA was moving to require its toughest warning labels on two popular diabetes drugs on the same day that Amgen put up $300 million [1] to acquire Alantos' lead product for the disease. Black Box warnings will now be put on Actos and Avandia, which has been the target of critics who maintain that the FDA has essentially done nothing to protect the public despite negative safety data. The upshot of this new move is a likely shift in the $10 billion diabetes drugs market toward other, newer therapies entering the market. That kind of flux is likely to draw the attention of other developers as well.

- read the article [2] from The Los Angeles Times

Related Articles:
Actos study points to reduction in heart attacks, strokes. Report [3]
New Avandia data unlikely to appease critics. Report [4]
Docs shunning Avandia in wake of safety study. Report [5]
Diabetes expert issued harsh Avandia critique in 2000. Report [6]
Avandia risks exposed under deal to post data. Report [7]